Joy Brownstein has more than 25 years experience providing marketing communications, corporate communications, corporate positioning and issues management counsel to clients in industries as diverse as healthcare, management consulting, financial services, telecommunications, environmental services, law and consumer products. For the past 16 years she has worked specifically in healthcare. She enjoys travel and has worked in Japan. During her time in Tokyo, Joy handled foreign media relations for an American biotech company who filed a lawsuit against a major Japanese company for patent violation and resulted in, the first time ever, a Japanese court ruling in favor of a foreign company. Joy is a graduate of Brown University. She resides in Westchester with her husband and two children.
January 25, 2012
Categories: Global Healthcare
Dr. Josh Bloom, director of chemical and pharmaceutical sciences at the American Council on Science and Health in New York, debated Dr. Els Torreele of the Open Society Foundation’s Access to Essential Medicine Initiative on the pages of Monday’s The Wall Street Journal on the subject of extending pharmaceutical patents. If you haven’t seen the special healthcare report section, make sure to pick it up or read it online because the pro and con opinions throughout the pages touch on topics ranging from whether universal health insurance is a good idea to the tension between electronic medical records and privacy, and whether it’s time for your physician to begin communicating with you by e-mail. Pharmaceutical Patents On pharmaceutical patents, those in favor of extension argue that longer patent protections would protect the profits needed to keep innovative product moving through the pipeline. Critics question whether there’s any link between patent life and innovation, and accuse drug companies of focusing on the most marketable drugs instead of those most urgently needed throughout the world. Dr. Bloom begins by recounting numbers familiar to most readers of VitalSigns. “… Bringing one new drug to market takes roughly 14 years, at a cost ofContinue Reading